1. Home
  2. ALLO vs RYAM Comparison

ALLO vs RYAM Comparison

Compare ALLO & RYAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • RYAM
  • Stock Information
  • Founded
  • ALLO 2017
  • RYAM 1926
  • Country
  • ALLO United States
  • RYAM United States
  • Employees
  • ALLO N/A
  • RYAM N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • RYAM Paper
  • Sector
  • ALLO Health Care
  • RYAM Basic Materials
  • Exchange
  • ALLO Nasdaq
  • RYAM Nasdaq
  • Market Cap
  • ALLO 427.7M
  • RYAM 495.7M
  • IPO Year
  • ALLO 2018
  • RYAM N/A
  • Fundamental
  • Price
  • ALLO $2.17
  • RYAM $7.39
  • Analyst Decision
  • ALLO Strong Buy
  • RYAM Buy
  • Analyst Count
  • ALLO 10
  • RYAM 1
  • Target Price
  • ALLO $10.06
  • RYAM $12.00
  • AVG Volume (30 Days)
  • ALLO 9.8M
  • RYAM 383.7K
  • Earning Date
  • ALLO 03-13-2025
  • RYAM 03-05-2025
  • Dividend Yield
  • ALLO N/A
  • RYAM N/A
  • EPS Growth
  • ALLO N/A
  • RYAM N/A
  • EPS
  • ALLO N/A
  • RYAM N/A
  • Revenue
  • ALLO $43,000.00
  • RYAM $1,630,290,000.00
  • Revenue This Year
  • ALLO N/A
  • RYAM $0.83
  • Revenue Next Year
  • ALLO N/A
  • RYAM $4.22
  • P/E Ratio
  • ALLO N/A
  • RYAM N/A
  • Revenue Growth
  • ALLO 26.47
  • RYAM N/A
  • 52 Week Low
  • ALLO $1.32
  • RYAM $3.15
  • 52 Week High
  • ALLO $5.78
  • RYAM $10.28
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 55.14
  • RYAM 45.95
  • Support Level
  • ALLO $1.32
  • RYAM $6.93
  • Resistance Level
  • ALLO $3.78
  • RYAM $7.41
  • Average True Range (ATR)
  • ALLO 0.36
  • RYAM 0.30
  • MACD
  • ALLO 0.10
  • RYAM -0.01
  • Stochastic Oscillator
  • ALLO 34.55
  • RYAM 28.98

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About RYAM Rayonier Advanced Materials Inc.

Rayonier Advanced Materials Inc manufactures high-purity cellulose derived from wood. Also known as cellulose specialties, the company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, High-Yield Pulp, and Corporate and Other. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of revenue from the United States.

Share on Social Networks: